Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.66 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.66 |
| ▸ | HRH3 | Q9Y5N1 | 2/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | RECQL | P46063 | 1/20 | 0.52 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.52 |
| ▸ | PSMB1 | P20618 | 2/20 | 0.46 |
| ▸ | PSMB5 | P28074 | 2/20 | 0.46 |
| ▸ | PSMB2 | P49721 | 2/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL270793 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4HRH3ALDH1A1RECQL | |
| SCHEMBL79031 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4ALDH1A1RECQLNR1I2 | |
| SCHEMBL9818198 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4ALDH1A1RECQLNR1I2 | |
| SCHEMBL4254052 | 0.86 | SMN1; SMN2 (0.68) | SMN1; SMN2CYP3A4HRH3ALDH1A1RECQL | |
| SCHEMBL24533728 | 0.86 | HRH3 (0.61) | SMN1; SMN2CYP3A4HRH3PSMB1PSMB5 | |
| SCHEMBL31422442 | 0.85 | SMN1; SMN2 (0.62) | SMN1; SMN2CYP3A4HRH3ALDH1A1RECQL | |
| SCHEMBL9476152 | 0.84 | HRH3 (0.59) | SMN1; SMN2CYP3A4HRH3ALDH1A1GAA | |
| SCHEMBL24533712 | 0.84 | HRH3 (0.55) | SMN1; SMN2CYP3A4HRH3ALDH1A1NR1I2 | |
| Alcohol SCHEMBL15135686 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP3A4HRH3ALDH1A1RECQL | |
| SCHEMBL5509217 | 0.82 | SMN1; SMN2 (0.64) | SMN1; SMN2CYP3A4HRH3ALDH1A1RECQL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230129152-A1 | Compounds Comprising Perfluorinated Group, Photoinitiator Group, and Amide Linking Group | 3M INNOVATIVE PROPERTIES COMPANY | 2023-04-27 | — | — | US | disclosed |
| US-11535709-B2 | Reactive end group containing polyimides and polyamic acids and photosensitive compositions thereof | PROMERUS, LLC (US) | 2022-12-27 | — | — | US | disclosed |
| US-20200283579-A1 | REACTIVE END GROUP CONTAINING POLYIMIDES AND POLYAMIC ACIDS AND PHOTOSENSITIVE COMPOSITIONS THEREOF | PROMERUS, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200285151-A1 | PHOTOSENSITIVE POLYIMIDE COMPOSITIONS | PROMERUS, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20200283580-A1 | UNSATURATED CYCLIC ANHYDRIDE END CAPPED POLYIMIDES AND POLYAMIC ACIDS AND PHOTOSENSITIVE COMPOSITIONS THEREOF | PROMERUS, LLC (US) | 2020-09-10 | — | — | US | disclosed |
| US-20170351147-A1 | LAMINATE AND OPTICAL FILM | FUJIFILM CORPORATION (JP) | 2017-12-07 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230129152-A1 | Compounds Comprising Perfluorinated Group, Photoinitiator Group, and Amide Linking Group | PFAS, AFF4, AFF1 | SMN1; SMN2 3826/4885CYP3A4 421/4885HRH3 4741/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.